Stocks and Investing
Stocks and Investing
Thu, December 21, 2017
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Wed, December 20, 2017
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Gena Wang Initiated (BCRX) at Hold and Held Target at $6 on, Dec 20th, 2017
Gena Wang of Barclays, Initiated "BioCryst Pharmaceuticals, Inc." (BCRX) at Hold and Held Target at $6 on, Dec 20th, 2017.
Gena has made no other calls on BCRX in the last 4 months.
There are 3 other peers that have a rating on BCRX. Out of the 3 peers that are also analyzing BCRX, 1 agrees with Gena's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Brian Abrahams of "RBC Capital" Initiated at Hold and Held Target at $6 on, Friday, September 15th, 2017
These are the ratings of the 2 analyists that currently disagree with Gena
- Jessica Fye of "JP Morgan" Upgraded from Hold to Buy on, Wednesday, September 6th, 2017
- Maury Raycroft of "Jefferies" Upgraded from Hold to Strong Buy on, Wednesday, September 6th, 2017
Contributing Sources